Halozyme Therapeutics Inc Sample Contracts

AutoNDA by SimpleDocs
BY AND AMONG
Securities Purchase Agreement • October 15th, 2004 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • New York
CREDIT AGREEMENT Dated as of May 24, 2022 among HALOZYME THERAPEUTICS, INC., as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, a Swing Line Lender and an L/C Issuer, and The Other Lenders and L/C Issuers Party Hereto BofA SECURITIES,...
Credit Agreement • May 24th, 2022 • Halozyme Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

This CREDIT AGREEMENT (“Agreement”) is entered into as of May 24, 2022, among HALOZYME THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), HALOZYME, INC., a California corporation, each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), each L/C Issuer (as hereinafter defined) from time to time party hereto and BANK OF AMERICA, N.A., as Administrative Agent and Swing Line Lender.

HALOZYME THERAPEUTICS, INC. 10,000,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement
Halozyme Therapeutics Inc • May 19th, 2017 • Biological products, (no disgnostic substances) • New York

Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 10,000,000 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,500,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.

RECITALS
Indemnity Agreement • July 23rd, 2004 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • Nevada
HALOZYME THERAPEUTICS, INC. ISSUER AND [_________________________], TRUSTEE INDENTURE
Halozyme Therapeutics Inc • June 10th, 2005 • Biological products, (no disgnostic substances) • New York
Exhibit 5.1 828,571 SHARES HALOZYME THERAPEUTICS, INC. SHARES OF COMMON STOCK ($0.001 PAR VALUE) PLACEMENT AGENT AGREEMENT
Halozyme Therapeutics Inc • December 14th, 2005 • Biological products, (no disgnostic substances) • New York
8,300,000 Shares HALOZYME THERAPEUTICS, INC. Common Stock ($0.001 par value) UNDERWRITING AGREEMENT
Underwriting Agreement • September 9th, 2010 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • New York

Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell 8,300,000 shares (the “Firm Stock”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, the Company proposes to grant to Barclays Capital Inc., as sole underwriter (the “Underwriter”), an option to purchase up to 1,245,000 additional shares of the Common Stock on the terms set forth in Section 2 (the “Option Stock”). The Firm Stock and the Option Stock, if purchased, are hereinafter collectively called the “Stock.” This is to confirm the agreement (this “Agreement”) concerning the purchase of the Stock from the Company by the Underwriter.

Exhibit 10.1 9,171,429 SHARES HALOZYME THERAPEUTICS, INC. SHARES OF COMMON STOCK ($0.001 PAR VALUE) PLACEMENT AGENT AGREEMENT
Halozyme Therapeutics Inc • December 13th, 2005 • Biological products, (no disgnostic substances) • New York
LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • August 9th, 2016 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances)

THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of June 7, 2016 (the “Effective Date”), among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and HALOZYME THERAPEUTICS, INC. a Delaware corporation (“Parent”) and HALOZYME, INC., a California corporation (“Halozyme”; Halozyme and Parent are individually and collectively, jointly and severally, “Borrower”), both with offices located at 11388 Sorrento Valley Road, San Diego, C

HALOZYME THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES
Halozyme Therapeutics Inc • February 28th, 2017 • Biological products, (no disgnostic substances) • New York

Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 5 Section 2.03 Denominations: Provisions for Payment 5 Section 2.04 Execution and Authentications 6 Section 2.05 Registration of Transfer and Exchange 7 Section 2.06 Temporary Securities 8 Section 2.07 Mutilated, Destroyed, Lost or Stolen Securities 8 Section 2.08 Cancellation 9 Section 2.09 Benefits of Indenture 9 Section 2.10 Authenticating Agent 9 Section 2.11 Global Securities 10 ARTICLE 3 REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS 10 Section 3.01 Redemption 10 Section 3.02 Notice of Redemption 10 Section 3.03 Payment Upon Redemption 11 Section 3.04 Sinking Fund 11 Section 3.05 Satisfaction of Sinking Fund Payments with Securities 12 Section 3.06 Redemption of Securities for Sinking Fund 12 ARTICLE 4 COVENANTS 12

HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of August 18, 2022 1.00% Convertible Senior Notes due 2028
Indenture • August 18th, 2022 • Halozyme Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

INDENTURE, dated as of August 18, 2022, between Halozyme Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity but solely as trustee, registrar, paying agent and conversion agent (the “Trustee”).

HALOZYME THERAPEUTICS, INC. STOCK OPTION AGREEMENT
Stock Option Agreement • May 5th, 2021 • Halozyme Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

Halozyme Therapeutics, Inc. has granted to the Participant named in the Notice of Grant of Stock Option (the “Grant Notice”) to which this Stock Option Agreement (the “Option Agreement”) is attached an option (the “Option”) to purchase certain shares of Stock upon the terms and conditions set forth in the Grant Notice and this Option Agreement. The Option has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Halozyme Therapeutics, Inc. 2021 Stock Plan (the “Plan”), as amended to the Date of Grant, the provisions of which are incorporated herein by reference. By signing the Grant Notice, the Participant: (a) acknowledges receipt of and represents that the Participant has read and is familiar with the Grant Notice, this Option Agreement, the Plan and a prospectus for the Plan in the form most recently registered with the Securities and Exchange Commission (the “Plan Prospectus”), (b) accepts the Option subject to all of the terms and conditi

HALOZYME THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES
Halozyme Therapeutics Inc • February 28th, 2017 • Biological products, (no disgnostic substances) • New York

Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificate 5 Section 2.3 Denominations: Provisions for Payment 5 Section 2.4 Execution and Authentications 6 Section 2.5 Registration of Transfer and Exchange 7 Section 2.6 Temporary Securities 8 Section 2.7 Mutilated, Destroyed, Lost or Stolen Securities 8 Section 2.8 Cancellation 9 Section 2.9 Benefits of Indenture 9 Section 2.10 Authenticating Agent 9 Section 2.11 Global Securities 9 ARTICLE III REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS 10 Section 3.1 Redemption 10 Section 3.2 Notice of Redemption 10 Section 3.3 Payment Upon Redemption 11 Section 3.4 Sinking Fund 11 Section 3.5 Satisfaction of Sinking Fund Payments with Securities 12 Section 3.6 Redemption of Securities for Sinking Fund 12 ARTICLE IV COVENANTS 12 Section 4.1

HALOZYME THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT
Restricted Stock Agreement • August 7th, 2009 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California

Halozyme Therapeutics, Inc. has granted to the Participant named in the Notice of Grant of Restricted Stock (the “Grant Notice”) to which this Restricted Stock Agreement (the “Agreement”) is attached an Award consisting of Shares subject to the terms and conditions set forth in the Grant Notice and this Agreement. The Award has been granted pursuant to the Halozyme Therapeutics, Inc. 2008 Stock Plan (the “Plan”), as amended to the Date of Grant, the provisions of which are incorporated herein by reference. By signing the Grant Notice, the Participant: (a) acknowledges receipt of and represents that the Participant has read and is familiar with the Grant Notice, this Agreement, the Plan and a Plan prospectus for the Shares in the form most recently registered with the Securities and Exchange Commission (the “Plan Prospectus”), (b) accepts the Award subject to all of the terms and conditions of the Grant Notice, this Agreement and the Plan and (c) agrees to accept as binding, conclusive

HALOZYME THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF ___, 20__ SUBORDINATED DEBT SECURITIES
Halozyme Therapeutics Inc • January 5th, 2010 • Biological products, (no disgnostic substances) • New York

indenture, dated as of [•], 200___, among Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):

Halozyme Therapeutics, Inc. Restricted Stock Units Agreement under the Halozyme Therapeutics, Inc. 2021 Stock Plan
Restricted Stock Units Agreement • August 8th, 2023 • Halozyme Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
HALOZYME THERAPEUTICS, INC. STOCK OPTION AGREEMENT
Stock Option Agreement • August 7th, 2009 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California

Halozyme Therapeutics, Inc. has granted to the Participant named in the Notice of Grant of Stock Option (the “Grant Notice”) to which this Stock Option Agreement (the “Option Agreement”) is attached an option (the “Option”) to purchase certain shares of Stock upon the terms and conditions set forth in the Grant Notice and this Option Agreement. The Option has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Halozyme Therapeutics, Inc. 2008 Stock Plan (the “Plan”), as amended to the Date of Grant, the provisions of which are incorporated herein by reference. By signing the Grant Notice, the Participant: (a) acknowledges receipt of and represents that the Participant has read and is familiar with the Grant Notice, this Option Agreement, the Plan and a prospectus for the Plan in the form most recently registered with the Securities and Exchange Commission (the “Plan Prospectus”), (b) accepts the Option subject to all of the terms and conditi

AutoNDA by SimpleDocs
FORM CEO CHANGE IN CONTROL AGREEMENT
Change in Control Agreement • February 28th, 2014 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California

This agreement is dated ___________ and is by and between HALOZYME THERAPEUTICS, INC., a Delaware corporation (the “Company,” “us,” “we” or “our”), and [_____________] (“you” or “your”).

Halozyme Therapeutics, Inc. Restricted Stock Award Agreement under the Halozyme Therapeutics, Inc. 2021 Stock Plan
Restricted Stock Award Agreement • May 5th, 2021 • Halozyme Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
INDEMNITY AGREEMENT
Indemnity Agreement • December 20th, 2007 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware

This Indemnity Agreement, dated as of December 14, 2007, is made by and between Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”).

HALOZYME THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT
Restricted Stock Agreement • August 7th, 2009 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California

Halozyme Therapeutics, Inc. has granted to the Participant named in the Notice of Grant of Restricted Stock (the “Grant Notice”) to which this Restricted Stock Agreement (the “Agreement”) is attached an Award consisting of Shares subject to the terms and conditions set forth in the Grant Notice and this Agreement. The Award has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Halozyme Therapeutics, Inc. 2008 Outside Directors’ Stock Plan (the “Plan”), as amended to the Date of Grant, the provisions of which are incorporated herein by reference. By signing the Grant Notice, the Participant: (a) acknowledges receipt of and represents that the Participant has read and is familiar with the Grant Notice, this Agreement, the Plan and a prospectus for the Plan in the form most recently registered with the Securities and Exchange Commission (the “Plan Prospectus”), (b) accepts the Award subject to all of the terms and conditions of the Grant Noti

6,150,000 Shares HALOZYME THERAPEUTICS, INC. Common Stock ($.001 par value) UNDERWRITING AGREEMENT
Underwriting Agreement • June 23rd, 2009 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • New York

Introductory. Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Jefferies & Company, Inc. as sole underwriter (“Jefferies” or the “Underwriter”) an aggregate of 6,150,000 shares (a “Share” and, collectively, the “Shares”) of common stock, $0.001 par value per share (the “Common Stock”) of the Company.

LEASE by and between BMR-SORRENTO PLAZA LLC, a Delaware limited liability company and HALOZYME, INC., a California corporation
Lease • June 16th, 2011 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California

THIS GUARANTY OF LEASE (“Guaranty”), dated as of June 10, 2011, is made and entered into by HALOZYME THERAPEUTICS, INC., a Delaware corporation (“Guarantor”).

FIRST AMENDMENT TO AMENDED AND RESTATED LEASE
Lease • July 5th, 2017 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances)

THIS FIRST AMENDMENT TO AMENDED AND RESTATED LEASE (this “Amendment”) is entered into as of this 30th day of June, 2017 (the “First Amendment Execution Date”), by and between BMR-11388 SORRENTO VALLEY ROAD LP, a Delaware limited partnership (“Landlord,” formerly known as BMR-11388 Sorrento Valley Road LLC), and HALOZYME, INC., a California corporation (“Tenant”).

HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of March 1, 2021 0.25% Convertible Senior Notes due 2027
Halozyme Therapeutics, Inc. • March 1st, 2021 • Biological products, (no disgnostic substances) • New York

INDENTURE, dated as of March 1, 2021, between Halozyme Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity but solely as trustee, registrar, paying agent and conversion agent (the “Trustee”).

SUBLEASE AGREEMENT between AVANIR PHARMACEUTICALS as Sublandlord and HALOZYME, INC. as Subtenant
Sublease Agreement • July 31st, 2007 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances)

THIS SUBLEASE AGREEMENT (“Sublease”) is made as of this 2nd day of July, 2007 (the “Effective Date”), by and between AVANIR PHARMACEUTICALS, a California corporation (“Sublandlord”) and HALOZYME, INC., a California corporation (“Subtenant”), a subsidiary of HALOZYME THERAPEUTICS, INC., a Nevada corporation (“Parent”), with Sublandlord and Subtenant hereinafter sometimes referred to collectively as the “Parties” and individually as a “Party”).

STOCK PURCHASE AGREEMENT Dated as of April 23, 2007 by and among HALOZYME THERAPEUTICS, INC. and NEW RIVER MANAGEMENT V, L.P.
Stock Purchase Agreement • April 24th, 2007 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California

This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of April 23, 2007, is entered into by and between Halozyme Therapeutics, Inc., a Nevada corporation (the “Company”), and New River Management V, LP, a Delaware limited partnership (the “Purchaser”), for the purchase and sale of 3,500,000 shares of the Company’s Common Stock, par value $.001 per share (the “Shares”).

NON-EXCLUSIVE DISTRIBUTION AGREEMENT
Non-Exclusive Distribution Agreement • April 23rd, 2004 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances)

THIS NON-EXCLUSIVE DISTRIBUTION AGREEMENT (this “Agreement”), dated as of February 9, 2004 (the “Effective Date”) is entered into between MediCult A/S (“Distributor”), CVR-no. 10975077, a Danish corporation, having a place of business located at Møllehaven 12, DK-4040 Jyllinge, Denmark, and HALOZYME THERAPEUTICS, INC. (“Halozyme”), a California corporation, having a principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, CA 92121. The parties hereby agree as follows:

AGREEMENT AND PLAN OF MERGER among HALOZYME THERAPEUTICS, INC., ATLAS MERGER SUB, INC. and ANTARES PHARMA, INC. Dated as of April 12, 2022
Agreement and Plan of Merger • April 13th, 2022 • Halozyme Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of April 12, 2022, by and among Halozyme Therapeutics, Inc., a Delaware corporation (“Parent”), Atlas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and Antares Pharma, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

TRANSITION SERVICES AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS
Consulting Agreement • September 29th, 2017 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California

This Transition Services Agreement and General Release of All Claims (“Agreement”) is made by and between Halozyme, Inc. (“Halozyme”) and Mark J. Gergen (“Employee”) with respect to the following facts:

Time is Money Join Law Insider Premium to draft better contracts faster.